Naghme Nazer,Hoda Mohammadzade,Mahya Mehrmohamadi Naghme Nazer

This can be particularly valuable in liquid biopsy where detecting small amounts of disease-specific cell-free DNA (cfDNA) amidst a bulk of healthy cfDNA is challenging.

Kevin J J Kwinten,Jean-Ellen Johnson,Anne M van Altena et al. Kevin J J Kwinten et al.

Novel approaches—such as biomarker-based detection using DNA methylation analysis of cervicovaginal samples, liquid biopsy techniques, and microbiome profiling—offer promising, non-invasive alternatives but require prospective validation in Lynch-specific populations.

Yiming Liu,Wei Wei,Hang Qi et al. Yiming Liu et al.

The TSGA platform provides a robust, label-free, and dynamically tunable approach for scalable nanoscale bioparticle processing, promising advances in exosome research and liquid biopsy diagnostics.

Audra J Schwalk,Muhammad Abu-Rmaileh,Horiana B Grosu Audra J Schwalk

Advances in next-generation sequencing and liquid biopsy technologies have enabled noninvasive detection of actionable mutations (EGFR, ALK, KRAS, PD-L1), enhancing molecular profiling directly from pleural samples.

Shuhong Guan,Junkang Huangfu,Xiaoqin Zhu et al. Shuhong Guan et al.

Background: Circulating tumor cells (CTCs) and peripheral T-cell immune checkpoints offer minimally invasive biomarkers for immune checkpoint inhibitor (ICI) therapy. We assessed whether a dual biomarker combining PD-L1 o...

Matthew Pelletier,B K Kleinschmidt-Demasters,Perry Corkos et al. Matthew Pelletier et al.

In addition to standard therapies, the Biocept IN/CNSide cerebrospinal fluid (CSF) liquid biopsy assay (Biocept, Inc., San Diego, California, US), including tumor cell protein expression biomarkers, ctDNA biomarkers, and tumor cell fluorescence in situ hybridization (FISH) biomarkers, was used to monitor

Yulia Shifrin,Asieh Alikhah,Zahabiya Husain et al. Yulia Shifrin et al.

The established technically robust liquid biopsy workflow enables 3D telomere profiling of MM CTCs that can be adopted for noninvasive MRD monitoring based on genomic instability rather than on the enumeration of MM plasma cells alone.Article HighlightsCurrent high-sensitivity assays for assessing minimal...residual disease (MRD) in multiple myeloma (MM) patients rely on invasive bone marrow sampling and are limited by sampling bias and poor suitability for frequent longitudinal monitoring.This study presents a proof-of-principle liquid biopsy workflow that enables isolation of morphologically intact circulating...blood (PB) using size-based filtration with the ScreenCell® device.Controlled spiking experiments with RPMI 8226 myeloma cells established an analytical limit of detection of approximately 1 tumor cell per 107 white blood cells.Technical feasibility of the new workflow for isolating intact CTCs from liquid...biopsy was confirmed in a cohort of 20 newly diagnosed MM patients at diagnosis, during induction therapy, and after relapse, supporting its potential utility for longitudinal disease monitoring.Isolated CTCs were successfully immunophenotyped and subjected to quantitative three-dimensional telomere

Andrew B Nixon,Fábio C P Navarro,Katherine I Zhou et al. Andrew B Nixon et al.

To explore whether ultra-sensitive circulating tumor DNA (ctDNA) profiling enables earlier prediction of treatment response and detection of disease progression, we applied NeXT Personal, an ultra-sensitive bespoke tumor-informed liquid biopsy platform, to profile tumor samples from the KeyLargo study...These results suggest that ultra-sensitive liquid biopsy approaches could improve treatment decision-making for mEGC patients receiving chemotherapy and immunotherapy.

Chunyan Wang,Jun Sun,Jianbo Song et al. Chunyan Wang et al.

The future of nano-immunotherapy lies in adaptive platforms that leverage liquid biopsy and computational modeling to dynamically counter the spatiotemporal evolution of resistance, offering a transformative paradigm for managing aggressive skin cancers.

Jessica K Lee,Julia C F Quintanilha,Kuei-Ting Chen et al. Jessica K Lee et al.

High concordance (sensitivity 88%) of amplification detection in liquid biopsy vs tissue was associated with higher AmpRatio and ctDNA tumor fraction ≥20%.